Autopsy report · NCT01284348
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
Cause of deathSlow enrollment
“Persistent low enrollment made study continuation no longer feasible”
Life of this trial
- Registered 3 months before it started.
- Ran for about 1 year 6 months before it stopped.
- 26 participants enrolled.
- Results were posted on the registry 11 years 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Industry
- Conditions
- Anemia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small-Cell Lung; Bladder Cancer; Cancer of Head and Neck; Uterine Cervical Cancer
- Interventions
- Sotatercept 15 mg; Sotatercept 30 mg
- Participants
- 26
Trials that died the same way
- LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis
“Study was discontinued due to slow enrollment” - Salvage Cryotherapy in Recurrent Prostate Cancer
“Study was ended due to low enrollment” - Hand Injected Ventriculography vs. Power Injected Left Ventriculography
“Study was stopped due to low enrollment.” - Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
“Study stopped due to slow enrollment” - A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels
“Study terminated early due to low enrollment”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.